JFJinhua Feng

Jinhua Feng

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Jinhua Feng has a total of 46 co-authors. Here are the top co-authors by number of shared publications:

  • Bairong Shen

    Department of Respiratory and Critical Care Medicine and Institutes for Systems Genetics, Frontiers Science Center for Disease-related Molecular Network, West China Hospital, Sichuan University, Chengdu, China

    2 shared publications
  • Bingqing Liu

    2 shared publications
  • Danting Li

    West China Hospital, Sichuan University

    2 shared publications
  • Erman Wu

    Joint Laboratory of Artificial Intelligence for Critical Care Medicine, Department of Critical Care Medicine and Institutes for Systems Genetics, Frontiers Science Center for Disease-related Molecular Network, West China Hospital, Sichuan University, Chengdu, China

    2 shared publications
  • Jiale Du

    2 shared publications
  • Rongrong Wu

    Joint Laboratory of Artificial Intelligence for Critical Care Medicine, Department of Critical Care Medicine and Institutes for Systems Genetics, Frontiers Science Center for Disease-related Molecular Network, West China Hospital, Sichuan University, Chengdu, China

    2 shared publications

Latest Publications

  • Open Access

    PEP-DSS-DBC1.0: A Personalized Exercise Prescription Decision Support System for Diabetes Care (Preprint)

    by Ting Bao, Xingyun Liu, Shumin Ren, Ke Zhang, Jiale Du, Danting Li, Bingqing Liu, Jinhua Feng, Rongrong Wu, Erman Wu, et al.

    BACKGROUND Exercise plays a critical role in managing diabetes, improving glycemic control, and reducing the risk of cardiovascular complications. However, personalizing exercise prescriptions (PEPs) to address individual characteristics and preferences is challenging, particularly in an environment with a global shortage of exercise professionals. While digital tools hold promise for improving personalized care, many existing systems rely on generalized guidelines or expert consensus, lacking the ability to provide highly individualized and evidence-based recommendations. To address this gap, we developed PEP-DSS-DBC1.0, a knowledge-based digital decision support system for generating tailored PEPs in diabetes care. OBJECTIVE The aim of this study was to create a digital, knowledge-based decision support tool for personalized exercise prescriptions that incorporates individual characteristics and preferences. PEP-DSS-DBC1.0 was designed to enhance the precision and usability of PEPs for people with diabetes while ensuring alignment with evidence-based principles. METHODS The development of PEP-DSS-DBC1.0 was informed by an extensive review of the literature. A working group, including experts in exercise medicine, diabetes care, and informatics, was formed to establish a decision support framework. The PubMed database served as the primary resource for knowledge extraction, covering studies published between January 1975 and May 2023. Data from 938 studies were annotated, resulting in 1,171 exercise protocols, 10,316,497 patient records, and 2,904 additional entries, totaling 13,263 data points. The web-based tool was built using a browser/server architecture and the WIMA (Windows, IIS, MySQL, ASP.NET) web stack. Validation and comparative analysis of the tool were performed against ChatGPT4o and sports physicians, using multiple metrics and two rating scales: the System Usability Scale (SUS) and the Net Promoter Score (NPS). RESULTS PEP-DSS-DBC1.0 provides personalized exercise prescriptions based on the newly developed “FITT-VP-WC” principles, which include frequency, intensity, time, type, volume, progression, warning, and contraindication. The tool demonstrated superior performance compared to ChatGPT4o and sports physicians, achieving a total performance score of 100% compared to 48% for ChatGPT4o and 12% for sports physicians (χ2=853.3, P<.001). Usability assessments showed that the average SUS score was 77.25 ± 6.06, indicating above-average usability, while the NPS score was 68.75%, reflecting high user loyalty and satisfaction. The tool is freely accessible at http://PEP-DSS-DBC.sysbio.org.cn/. CONCLUSIONS PEP-DSS-DBC1.0 represents a significant advancement in diabetes care, providing a knowledge-based system for generating highly individualized exercise prescriptions. While the tool has demonstrated superior performance and usability, future randomized controlled trials are essential to further validate its clinical utility and broader application in diabetes management.

  • Prevention of exercise-related injuries and adverse events in patients with diabetes:a scoping review

    by Ting Bao, Bingqing Liu, Danting Li, Jiale Du, Jinhua Feng, Xingyun Liu, Rongrong Wu, Shumin Ren, Erman Wu, Wei Gao, et al.

    INPLASY2023110047 Prevention of exercise-related injuries and adverse events in patients with diabetes:a scoping review Keywords: Diabetes; scoping review; exercise; physical activity; adverse even…

  • Retraction
    Open Access

    Retraction Note: Down-regulation of microRNA-342-5p or Up-regulation of Wnt3a Inhibits Angiogenesis and Maintains Atherosclerotic Plaque Stability in Atherosclerosis Mice

    by Haixia Sun, Jinhua Feng, Yan Ma, Ding Cai, Yulu Luo, Qinggong Wang, Fang Li, Mingyue Zhang, Quanzhong Hu

  • Open Access

    Association between compliance with enhanced recovery after surgery (ERAS) protocols and postoperative outcome in patients with primary liver cancer undergoing hepatic resection

    by Jinhua Feng, Ka Li, Ruihua Xu, Huan Feng, Qiang Han, Hui Ye, Fuyu Li

    Background: Enhanced recovery after surgery (ERAS) is a multidisciplinary, stress-minimizing approach that is associated with improved postoperative outcomes. However, whether the level of compliance with ERAS protocols impacts the postoperative outcome of patients with primary liver cancer undergoing liver resection is unknown. The study aimed to analyze the association between compliance with ERAS protocols and liver resection outcomes. Methods: This prospective cohort study consecutively recruited patients with primary liver cancer who were scheduled for elective liver surgery between January 2019 and December 2020 at the Department of Biliary Surgery, West China Hospital of Sichuan University. Twenty individual ERAS items were assessed in all patients. The patients were divided into two groups according to their degree of compliance with the ERAS interventions: an ERAS-compliant (ERAS-C) group of individuals who complied with over 75% of the ERAS components and an ERAS-noncompliant (ERAS-N) group. The primary outcomes were ERAS compliance, occurrence of major complications within 30 days postoperatively, and length of postoperative hospital stay. The secondary outcomes were 30-day readmissions, reoperations and other rehabilitation indicators. The study was registered at www.chictr.org.cn (identity number ChiCTR2000040021). Results: Overall, 436 patients were enrolled; their mean age was 54 years (interquartile range [IQR], 47–66). Of these patients, 206 were allocated to the ERAS-C group, and the other 230 patients comprised the ERAS-N group. The overall compliance rate was 70% (IQR, 65%-80%). The ERAS-C group had higher compliance rates [80.00% (IQR, 75.00–85.00%)] than the ERAS-N group [65.00% (IQR, 65.00–70.00%)], P < 0.001). The ERAS-C group had significantly fewer major complications (7.77% vs. 15.65%, OR, 0.449, 95% CI, 0.241–0.836, P = 0.012) and shorter postoperative hospital stays (5 days [IQR, 4–6] vs. 6 days [IQR, 5–7], P < 0.001) than the ERAS-N group. Subgroup analysis indicated that compliance rates greater than 80%, between 65 and 80%, and lower than 65% were associated with decreased major complication rates (6.25%, 8.48% and 22.83%, respectively) and shorter postoperative hospital stays. However, the rates of ICU stay, readmission, reoperation and mortality within 30 days after surgery were not different between groups (P > 0.05). Conclusion: The results of this study suggest that higher compliance with ERAS components is associated with a lower incidence of major postoperative complications and a shorter postoperative hospital stay.


  • [Efficacy of local infiltration of ropivacaine combined with multimodal analgesia with parecoxib for perioperative analgesia in patients undergoing pancreaticoduodenectomy].

    by Jinhua Feng, Ka Li, Huan Feng, Qiang Han, Min Gao, Ruihua Xu

    To explore the effect of local infiltration of ropivacaine combined with multimodal analgesia with parecoxib for perioperative pain management in patients undergoing pancreaticoduodenectomy. This randomized controlled trial was conducted among 98 patients undergoing pancreaticoduodenectomy in the Department of Biliary Surgery of West China Hospital between March, 2017 and August, 2018. The patients were randomized to receive perioperative analgesia with local infiltration anesthesia with ropivacaine combined with multimodal analgesia with parecoxib (experimental group, n=50) or postoperative analgesia with dizosin (control group, n=48). The regimens for intraoperative anesthesia and postoperative pain relief were identical in the two groups. The differences in NRS pain score, use of pain relief agents, the incidences of adverse reactions to analgesia and wound infection, and the time to first ambulation and first flatus passage after the operation were compared between the two groups. At 12, 24 h, 48 h, 72 h and 7 days after the operation, the patients in the experimental group had significantly lower NRS scores (P < 0.05) than those in the control group. The rate of use of rescue analgesics was significantly lower in the experimental group than in the control group (32% vs 66.67%, P < 0.05); the rate of tramadol hydrochloride use was also significantly lower in the experimental group (P < 0.05). Compared with those in the control group, the patients in the experimental group showed a significantly lower total incidence of adverse reactions (22% vs 54.17%, P < 0.05) as well as a lower incidence of nausea and vomiting (P < 0.05), an earlier time of first ambulation and first flatus passage after the operation (P < 0.05), and a shorter postoperative hospital stay (P < 0.05). In patients undergoing pancreaticoduodenectomy, local infiltration of ropivacaine combined with multimodal analgesia with ropivacaine can effectively relieve perioperative pain, reduce the use of relief analgesics, lower the incidence of adverse reactions, and promote the recovery after the surgery.


  • Randomized phase II study of biweekly gemcitabine (gem)-paclitaxel (pac), gem-carboplatin (carb) and gem-cisplatin (cis) as first-line treatments in metastatic breast cancer (MBC) after anthracycline failure

    by B. Xu, Z. Jiang, S. Kim, S. Yu, J. Feng, A. Malzyner, A. Del Giglio, H. Chung, M. Yu, A. Serrano

    1099 Background: Biweekly gem-pac and gem-cis regimens have shown promising activity and safety in different tumor types. In MBC biweekly gem-pac is active and well tolerated. The aim of this multi-country study is to evaluate the efficacy and safety of gem in combination with pac, carb or cis on a biweekly schedule in patients (pts) with MBC. Methods: Major eligibility criteria included: tissue diagnosis of stage IV breast carcinoma; prior anthracycline therapy; ECOG performance status (PS) of 0 or 1; and written informed consent. Pts were randomized to receive gem 2500 mg/m2 in combination with pac 150 mg/m2 (Arm A), carb AUC 2.5 (Arm B) or cis 50 mg/m2 (Arm C) on day 1 of 2-week cycles. The primary endpoint was response rate, with safety a secondary endpoint. Results: This interim analysis was planned to occur when patient enrollment had reached 50% (75/150 pts), at which point there were 26 pts in Arm A, 25 in Arm B and 24 in Arm C, with 12 pts still on treatment. The baseline characteristics were similar in the three arms, including mean age (Arm A 50.2 yr, Arm B 46.1, Arm C 47.3); ECOG PS (PS 0: 50.0%, 64.0%, 54.2%); mean number of sites of tumor involvement (2.9, 2.6, 2.7); dominant type of metastasis (visceral: 73.1%, 80.0%, 79.2%); and disease-free interval (<24 mo: 53.8%, 60.0%, 41.7%). The mean number of cycles was 6.4, 6.0 and 5.8. There was a partial response in 5/26 efficacy qualified pts (19.2%), 5/25 pts (20.0%) and 2/23 pts (8.7%) in Arms A, B and C, respectively, stable disease in 10 pts (38.5%), 9 pts (36.0%) and 9 pts (39.1%), and progressive disease in 5 pts (19.2%), 6 pts (24.0%) and 6 pts (26.1%). There were no treatment-related deaths. Conclusions: The three regimens appear to show activity and have manageable toxicity when given on a biweekly schedule. No significant financial relationships to disclose.